European journal of breast health最新文献

{"title":"Three Dimensional Modelling in the Optimisation of Chest Wall Resection and Reconstruction Following Metastatic Breast Cancer.","authors":"Hanad Ahmed,&nbsp;Mansoor Khan,&nbsp;Aiman Alzetani","doi":"10.4274/ejbh.galenos.2022.2022-3-6","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2022.2022-3-6","url":null,"abstract":"<p><p>Two-dimensional computed tomography scans no longer offer the level of detail that many surgeons desire for more accurate and precise surgical intervention. Computed tomography image reconstruction into three dimensional (3D) virtual models with interactive capability is providing an enhanced understanding of the patient's anatomy and pathology allowing the surgeon to create tailored intraoperative plans, minimizing complications and maximizing the intended therapeutic outcome. In this case report we demonstrate the use of 3D image reconstruction software in the management of a 36-year-old female with metastatic breast cancer affecting the chest wall.</p>","PeriodicalId":11885,"journal":{"name":"European journal of breast health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255651/pdf/ejbh-18-286.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40606406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Overview of the Impact of Body Mass Index on Pathological Complete Response Following Neoadjuvant Chemotherapy in Operable Breast Cancer in a Tertiary Care Centre in South India.","authors":"S P Somashekhar,&nbsp;Richa Jaiswal,&nbsp;Rohit Kumar,&nbsp;B C Ashok,&nbsp;Susmita Rakshit,&nbsp;Amit Rauthan,&nbsp;Poonam Patil,&nbsp;Nitin Yashas,&nbsp;H K Karthik,&nbsp;Archa Prasad,&nbsp;Herra Islam,&nbsp;K R Ashwin","doi":"10.4274/ejbh.galenos.2022.2022-2-5","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2022.2022-2-5","url":null,"abstract":"<p><strong>Objective: </strong>The incidence of female breast cancer in the world is 11.7% with a mortality rate of 6.9%. According to Globocon 2020, breast cancer is the most commonly diagnosed cancer (24.5%) and the leading cause of cancer-related death amongst women worldwide. The purpose of this study was to analyze the impact of Body Mass Index (BMI) on pathological complete response (pCR) rates for operable breast cancer after neoadjuvant chemotherapy (NACT). The primary endpoint was to assess histopathological features of the surgical specimen in response to NACT and to investigate the relationship with pre-chemotherapy BMI taking into account the various molecular subtypes of breast cancer.</p><p><strong>Materials and methods: </strong>Patients with biopsy-proven breast carcinoma who underwent surgery after NACT between January 2017 and May 2021 were included. All patients were initially divided into three groups depending on their pre-chemotherapy BMI. With BMI <22.9 as normal or underweight category, BMI of 23-27.4, was taken as overweight category and BMI ≥27.5 as obese category.</p><p><strong>Results: </strong>The study included 184 patients. Normal weight patients had the highest rate of pCR (75%) and the lowest was seen in the obese category (33.75%). Furthermore, the subtype most likely to achieve pCR was HER2+/ER negative followed by triple negative BC with odds ratios of 3.46 and 2.21, respectively.</p><p><strong>Conclusion: </strong>This retrospective study established that overweight and obese patients suffering from breast carcinoma had a lessened pCR rate following NACT in comparison with those who were under-/normal weight.</p>","PeriodicalId":11885,"journal":{"name":"European journal of breast health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255653/pdf/ejbh-18-271.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40618490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stereotaxic Core-Needle Biopsy in Assessing Intraductal Pathologic Findings at Ductography.","authors":"G A Belonenko,&nbsp;N A Sukhina,&nbsp;A A Aksyonov,&nbsp;E G Aksyonova","doi":"10.4274/ejbh.galenos.2022.2022-3-7","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2022.2022-3-7","url":null,"abstract":"<p><strong>Objective: </strong>The purpose of this study was to analyze the capabilities of ductography (DG) to navigate stereotactic core-needle biopsy (sCNB) for localizing and differentiating intraductal benign and malignant proliferations of the breast in patients with pathological nipple discharge (PND).</p><p><strong>Materials and methods: </strong>Patients underwent physical, radiological, ultrasound, endoscopic and histopathological examinations.</p><p><strong>Results: </strong>The study included 183 patients. In 51, traditional DG was performed and in eight patients DG was performed using endoscopic mammoductoscopy (EMDS). A routine ductectomy labeled with methylene blue or propylene thread was performed in 81 patients. In 77 cases, a ductectomy was performed after double wire marking of intraductal proliferations (IDP) through the nipple and through the skin. In 26 patients, a preoperative sCNB under guidance of DG was performed. After sCNB 23/26 patients had benign IDP and three (11.5%) had invasive cancer. Breast surgery confirmed histology to be the gold standard in all patients, with the exception of 7 (26.9%) under the age of 45 years with benign IDP. These patients had watchful waiting and after 35 months of follow-up no signs of malignant growth were detected.DG was characterized by high (87.9%) sensitivity and low (33.3%) specificity. False positive rate was 25.9% and the cause was peripheral location of IDP (>3 cm from the nipple) in 57.1% and inadequate excision with leaving them outside the resection.</p><p><strong>Conclusion: </strong>This initial study on sCNB under the guidance of traditional or selective DG reports promising findings. Further studies are needed to determine whether preoperative histological assessment of pathologic intraductal lesions at DG would reduce the number of open surgeries with benign histology at sCNB.</p>","PeriodicalId":11885,"journal":{"name":"European journal of breast health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255652/pdf/ejbh-18-279.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40618494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between GATA3 and Histopathological and Immunohistochemical Parameters in Early-Infiltrating Breast Carcinomas.","authors":"Priscila de Medeiros Souza,&nbsp;Filomena Marino Carvalho,&nbsp;Fernando N Aguiar,&nbsp;Débora Gagliato,&nbsp;Alfredo Carlos Simões Dornellas de Barros","doi":"10.4274/ejbh.galenos.2022.2022-3-9","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2022.2022-3-9","url":null,"abstract":"<p><strong>Objective: </strong>This study evaluated the frequency of GATA-binding protein 3 (GATA3) expression in early breast cancer and its relationship with histopathological and immunohistochemical parameters.</p><p><strong>Materials and methods: </strong>GATA3 was analysed by immunohistochemistry in histological sections of tumors from 105 female patients, with histological diagnosis of invasive breast carcinoma (BC), at clinical stages I, II and IIIA, who underwent primary surgical treatment. GATA3 nuclear expression was determined as the percentage of positive tumor cells and further categorized as high (positive expression in more than 95% of cells) or non-high (negative or low positive expression in up to 95% of tumor cells). GATA3 expression was analysed according to the patient age, tumor and node pathological stage, histological type, histological and nuclear grade, lymphovascular invasion, and estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR), human epidermal growth factor 2 (HER2) status, and Ki-67 expression.</p><p><strong>Results: </strong>GATA3 expression was positive in 103 cases (98.1%). High expression was significantly associated with low histological and nuclear grade, positive hormonal receptors, and less proliferative activity based on Ki-67 expression. A prominent feature was that 94.7% of the ER-positive/HER2-negative cases presented high-GATA3 expression, as 94.0% of the tumors showing high-GATA3 were ER-positive. In ER-negative/HER2-positive or ER-negative/HER2- negative, high-GATA3 was present in 25% while 75% were non-high-GATA3 compared with ER-positive/HER2- negative (4.1%) and ER-positive/HER2-positive (20%). Proliferative activity in triple-negative breast cancer tended to be higher among tumors with low-GATA3, irrespective of AR expression. In the group of ER-positive/HER2-negative tumors only three cases were low-GATA3 (85% and 80%), both with high proliferative activity.</p><p><strong>Conclusion: </strong>High GATA3 expression is associated with favorable histopathologic and immunohistochemical BC prognostic factors.</p>","PeriodicalId":11885,"journal":{"name":"European journal of breast health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255655/pdf/ejbh-18-229.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40606405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Factors for Success and Lack of Success in the Breast Cancer Patient Care Pathway: A Qualitative Study From the Health Care Staff Perspective.","authors":"Eija Metsälä,&nbsp;Tanja Schroderus-Salo,&nbsp;Kjersti Straume,&nbsp;Bergliot Strom,&nbsp;Laurent Marmy,&nbsp;Mona Øynes,&nbsp;José A Pires Jorge,&nbsp;Liis Randle,&nbsp;Siret Kivistik","doi":"10.4274/ejbh.galenos.2022.2022-3-1","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2022.2022-3-1","url":null,"abstract":"<p><strong>Objective: </strong>To produce information about factors related to successful and unsuccessful breast cancer care pathways from the health care staff perspective.</p><p><strong>Materials and methods: </strong>An electronic qualitative survey was used to collect data simultaneously from hospitals located in four different countries, focusing on four professional groups: diagnostic radiographers; radiation therapists; breast cancer nurses; and biomedical laboratory scientists (n = 23). The hospitals participating in the study treat breast cancer patients and research permits were applied from all of them. Data was analysed by deductive thematic analysis.</p><p><strong>Results: </strong>At the core of a successful breast cancer care pathway is the right content and timely information provided to the patient at the pace the patient is able to adopt. This is especially highlighted at the beginning of the treatment process. In regards to diagnostic services, rigorous execution of mammography, sampling techniques and analyses were seen as important. Staff also valued the importance of aftercare and follow-up, and highlighted the fact that the patient should be given a chance to keep in close contact with care and treatment staff, even after their active treatment process has finished.</p><p><strong>Conclusion: </strong>Health care staff recognized the same success factors for optimal breast cancer care and treatment pathways as patients reported in previous studies, yet more emphasis was put on patient characteristics and the technical performance features of the process. Both patient and staff viewpoints should be taken into account in planning breast cancer care pathways.</p>","PeriodicalId":11885,"journal":{"name":"European journal of breast health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255659/pdf/ejbh-18-222.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40618488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An <i>In Silico</i> Analysis Identified Members of the Pleckstrin Homology-Like Domain, Family B (PHLDB family) as Potential Prognostic and Predictive Biomarkers of Treatment Response in Breast Cancer Patients.","authors":"Renan Gomes do Nascimento,&nbsp;Jéssica de Moraes,&nbsp;Danilo de Oliveira Cerqueira,&nbsp;Sandro Jorge Januário","doi":"10.4274/ejbh.galenos.2022.2022-3-5","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2022.2022-3-5","url":null,"abstract":"<p><strong>Objective: </strong>Breast cancer is the leading cause of morbidity and mortality in women worldwide. This malignant neoplasm can be classified into four clinically relevant subtypes according to the expression of a number of biomarkers. However, these tumors show considerable intratumoral heterogeneity and multidrug resistance. Members of the pleckstrin homology-like domain, family B (PHLDB) play a critical role in the regulation of p53 and AKT signaling pathways, important for cancer and cellular metabolism. The present study was performed to evaluate the expression pattern of PHLDB family members in breast cancer and its potential prognostic and predictive value for therapeutic response using bioinformatics tools.</p><p><strong>Materials and methods: </strong>This in silico analysis was performed using several online repositories, including UALCAN, GEPIA2, bc-GenExMiner, KM Plotter, PrognoScan and ROC Plotter.</p><p><strong>Results: </strong>PHLDB family genes were found to be differentially expressed in tumor samples when compared to healthy breast tissue samples. Furthermore, epigenetic regulation may be one of the regulatory mechanisms for the expression of these markers. The PHLDB family of genes proved to be potential markers for predicting the development of lymph node metastasis (<i>p</i><0.0001) and poor clinical outcome. All members of the PHLDB family were significantly correlated with hormone receptors. High levels of PHLDBs expression were associated with worse overall survival and recurrence-free survival in breast cancer patients. Finally, our data demonstrate that members of the PHLDB family can be promising markers in the stratification of patients who may or may not respond to different available therapies.</p><p><strong>Conclusion: </strong>Our cumulative results demonstrate that PHLDB family members may be promising biomarkers for predicting prognosis and therapeutic response in breast cancer patients.</p>","PeriodicalId":11885,"journal":{"name":"European journal of breast health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255658/pdf/ejbh-18-235.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40618492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Senologic International Society Survey on Ductal Carcinoma <i>In Situ</i>: Present and Future.","authors":"Carole Mathelin,&nbsp;Massimo Lodi,&nbsp;Khalid Alghamdi,&nbsp;Bolivar Arboleda-Osorio,&nbsp;Eli Avisar,&nbsp;Stanley Anyanwu,&nbsp;Mohcen Boubnider,&nbsp;Mauricio Maghales Costa,&nbsp;Elisabeth Elder,&nbsp;Tony Elonge,&nbsp;Luiz Gebrim,&nbsp;Xishan Hao,&nbsp;Shigeru Imoto,&nbsp;Esther Meka,&nbsp;Michel Mouelle,&nbsp;Alexander Mundinger,&nbsp;Valerijus Ostapenko,&nbsp;Serdar Özbaş,&nbsp;Tolga Özmen,&nbsp;Vahit Özmen,&nbsp;Tadeusz Pienkowski,&nbsp;Gustavo Sarria,&nbsp;Ashraf Selim,&nbsp;Vladimir Semiglazov,&nbsp;Schlomo Schneebaum","doi":"10.4274/ejbh.galenos.2022.2022-4-3","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2022.2022-4-3","url":null,"abstract":"<p><strong>Objective: </strong>Therapeutic management of ductal carcinoma <i>in situ</i> (DCIS) is heterogeneous among countries worldwide, and some treatment indications are still controversial. To investigate DCIS management in different countries; identify both consensual practices and controversial topics; and survey opinions about the future management of DCIS.</p><p><strong>Materials and methods: </strong>The Senologic International Society network members participated to an online survey using a questionnaire, between November 2021 and February 2022.</p><p><strong>Results: </strong>Twenty-two responses from 20 different countries showed that organized breast cancer screening programs were present for 87% participants, and DCIS cases represented 13.7% of all breast cancers. Most participants used the grade classification (100%), the morphological classification (78%) and performed immunohistochemistry assays (73%). In case of conservative treatment, the mean re-excision rate was 10.3% and clear margins of mean 2.5 mm were considered healthy. Radical mastectomy rate was 35.5% with a breast reconstruction rate of 53%. Tumor bed boost indications were heterogeneous, and 73% of participants indicated hormone therapy for hormone-positive DCIS. Surgery and radiotherapy omission for some low-risk DCIS were considered by 73% of participants. Multigene assays were used by 43% of participants. Concerning future changes in DCIS management, participants mostly answered surgical de-escalation (48%), radiotherapy de-escalation (35) and/or active surveillance for some cases (22%).</p><p><strong>Conclusion: </strong>This survey provided an overview of the current practices of DCIS management worldwide. It showed that some areas are rather consensual: incidence increases over time, treatment in young women, pathological classifications, definition of healthy margins, the skin-sparing mastectomy and immediate breast reconstruction. However, some topics are still debated and result in heterogeneous practices, such as evolution in the age of diagnosis, the benefit of de-escalation in low-risk DCIS among elderly women, indications for hormone therapy, radiotherapy omission, or multigene assays. Further evidence is needed to reach consensus on these points, and innovative approaches are still under evaluation in clinical trials. The International Senologic Society, by its members, encourages precision medicine and personalized treatments for DCIS, to avoid overtreatment and overdiagnosis, and provide better healthcare to women with DCIS.</p>","PeriodicalId":11885,"journal":{"name":"European journal of breast health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255660/pdf/ejbh-18-205.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40606404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Update of the 100 Most Cited Articles on Breast Cancer: A Bibliometric Analysis.","authors":"Ahmet Necati Şanlı","doi":"10.4274/ejbh.galenos.2022.2022-3-8","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2022.2022-3-8","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to perform a bibliometric analysis of the 100 most cited articles related to breast cancer.</p><p><strong>Materials and methods: </strong>The research was done on the Web of Science (WOS) database. Only research articles were included in the study. Results were obtained by typing the term \"breast cancer\" in the WOS Search box. The results were sorted according to the number of WOS core citations and all database citations, the first author of the article, the institution of the first author, publication year, article category, and countries.</p><p><strong>Results: </strong>The most cited article had 10236 citations. Nearly three-quarters (70%) of the articles were from the USA and most articles were published by Harvard University. Thirty-seven percent of the articles were in the medicine, general and internal medicine categories.</p><p><strong>Conclusion: </strong>This bibliometric analysis identified the 100 most cited research articles about breast cancer and provided a record of historical developments and trends in breast cancer research.</p>","PeriodicalId":11885,"journal":{"name":"European journal of breast health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255650/pdf/ejbh-18-258.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40618493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Open-Label Three Arm Trial Comparing Ormeloxifene, Gamma Linolenic Acid With Methylcobalamine + Vitamin C and Placebo in Mastalgia.","authors":"Amrendra Verma,&nbsp;Deepti Bala Sharma,&nbsp;Sanjay Kumar Yadav,&nbsp;Dhananjaya Sharma","doi":"10.4274/ejbh.galenos.2022.2022-2-6","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2022.2022-2-6","url":null,"abstract":"<p><strong>Objective: </strong>We evaluated the beneficial effect of Ormeloxifene (Centchroman) versus a combination of Gamma Linolenic acid (GLA), methylcobalamine and vitamin C on mastalgia in a three-arm, open-label, placebo-controlled trial.</p><p><strong>Materials and methods: </strong>Patients aged above 18 years with mastalgia were recruited between January 2019 and July 2021. Patients were divided in three arms: Ormeloxifene arm, GLA arm and Placebo arm. Response was evaluated using visual analogue scale (VAS) and score below 3/10 was defined as complete relief.</p><p><strong>Results: </strong>A total of 113 consecutive women with mastalgia were randomized to the GLA group (Group 1, n = 39 women), Ormeloxifene (Group 2, n = 36) and Placebo (Group 3, n = 38). Complete response was observed in 94% patient in Group 1, 96% in Group 2 and 87% in Group 3 at the end of 12 weeks and it was not significant (<i>p</i> = 0.49). Adverse events were reported by eleven patients taking Ormeloxifene, compared to none in the other two groups.</p><p><strong>Conclusion: </strong>In this study Ormeloxifene and GLA were not superior to placebo for pain relief in mastalgia. Furthermore, there were concerning side effects associated with Ormeloxifene therapy. The role of Ormeloxifene in mastalgia needs further evaluation before recommending it as preferred therapy.</p>","PeriodicalId":11885,"journal":{"name":"European journal of breast health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255657/pdf/ejbh-18-248.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40618489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Value of Tyrer-Cuzick Versus Gail Risk Modeling in Predicting Benefit from Screening MRI in Breast Cancer.","authors":"Anthanasios Sevdalis,&nbsp;Xiaoyan Deng,&nbsp;Dipankar Bandyopadhyay,&nbsp;Kandace P McGuire","doi":"10.4274/ejbh.galenos.2021.2021-8-2","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2021.2021-8-2","url":null,"abstract":"<p><strong>Objective: </strong>Breast cancer is the most commonly diagnosed malignancy in US women. Risk assessment tools such as the Gail and Tyrer-Cuzick (TC) models calculate risk for breast cancer based on modifiable and non-modifiable factors in order to guide screening and prevention for high-risk patients. Screening with magnetic resonance imaging (MRI) in addition to mammography is recommended in high-risk patients (>20% lifetime risk on TC or other familial based models). Currently, no published data indicate these recommendations improve cancer detection.</p><p><strong>Materials and methods: </strong>With the aim to determine what percentage lifetime risk (LR%) is associated with a statistically significant increase in cancer detection, the Virginia Commonwealth University (VCU) breast imaging database was reviewed to identify patients who received screening MRI.</p><p><strong>Results: </strong>The receiver operating characteristics (ROC) curves for the Gail and TC models and the rate of cancer detection correlated to 20% LR% were calculated. The Gail model was considered the control model as it is NOT considered a validated screening tool for MRI. TC is not more accurate than Gail when predicting benefit of breast MRI screening. (area under the curve (AUC): 0.6841, 0.6543 respectively, p = 0.828). Univariate analysis failed to demonstrate a statistically significant relationship between the Gail or TC LR % and diagnosis of breast cancer when using 20% as the cutoff for high-risk classification (p = 1.0, 0.369 respectively). Neither the TC nor the Gail risk calculators demonstrated a significant correlation between risk and the likelihood of diagnosis of breast cancer when screened with MRI.</p><p><strong>Conclusion: </strong>Larger cohort studies are necessary to determine the risk percentage most predictive of a breast cancer diagnosis using MRI as screening.</p>","PeriodicalId":11885,"journal":{"name":"European journal of breast health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734526/pdf/ejbh-18-79.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10612959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}